menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Albireo`s Bylvay (Odevixibat) Approved In Europe

    EMA

    Ipsen completes acquisition of Albireo, expanding the scope of Rare Disease

    GLOBENEWSWIRE

    Ipsen extends expiration date of tender offer for Albireo to 1 March 2023

    GLOBENEWSWIRE

    FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome

    GLOBENEWSWIRE

    Failed deal, bidding war paved the way for Ipsen`s $952M rare disease buyout

    ENDPTS

    Ipsen to Acquire Albireo Accelerating Growth in Rare Disease

    BUSINESSWIRE

    Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA

    GLOBENEWSWIRE

    Albireo Appoints Paul Streck, M.D., as Chief Medical Officer

    GLOBENEWSWIRE

    Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Reimbursed Access to (odevixibat) Approved in France for Patients PFIC 1 & 2

    GLOBENEWSWIRE

    Reimbursed Access to Bylvay Approved in France for Patients with PFIC 1 & 2

    GLOBENEWSWIRE

    Albireo to Participate in Jefferies London Healthcare Conference

    GLOBENEWSWIRE

    Albireo Reports Q3 2022 Financial Results and Business Update

    GLOBENEWSWIRE

    Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022

    GLOBENEWSWIRE

    Albireo Announces 2022 SPARK Grant Winners

    GLOBENEWSWIRE

    Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia

    GLOBENEWSWIRE

    Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022

    GLOBENEWSWIRE

    Albireo to Report Q3 2022 Financial Results on November 8, 2022

    GLOBENEWSWIRE

    Mirum gains an edge over rival Albireo in pediatric liver disease

    FIERCEPHARMA

    Mirum gets a leg up on Albireo in pediatric liver disease

    FIERCEPHARMA

    Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® NASPGHAN

    GLOBENEWSWIRE

    Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV)

    GLOBENEWSWIRE

    Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay

    GLOBENEWSWIRE

    Albireo`s Bylvay aces test in Alagille syndrome, setting for liver disease nod

    FIERCEPHARMA

    Albireo to Showcase New Data at AASLD The Liver Meeting® 2022

    GLOBENEWSWIRE

    Liver-focused startup nabs $115M in exchange for rare disease drug royalties

    ENDPTS

    Albireo Pharma (ALBO) Stock Jumps 11%: Will It Continue to Soar?

    NASDAQ

    Albireo Announces $115 Million Royalty Monetization Agreement with Sagard

    GLOBENEWSWIRE

    Albireo to Participate in Guggenheim Nantucket Therapeutics Conference

    GLOBENEWSWIRE

    Italian Medicines Agency Approves Reimbursed Access to Bylvay® (odevixibat)

    GLOBENEWSWIRE

    Albireo to Participate in Upcoming Investor Conferences

    GLOBENEWSWIRE

    Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Medison Pharma Expands Partnership with Albireo to a Multi-Regional Agreement

    PRNEWSWIRE

    Albireo Reports Q2 2022 Financial Results and Business Update

    GLOBENEWSWIRE

    Albireo Appoints New Members to Board of Directors

    GLOBENEWSWIRE

    Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference

    PRESS RELEASE

    Albireo to Report Q2 2022 Financial Results on August 15, 2022

    GLOBENEWSWIRE

    Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Albireo to Present at the William Blair Biotech Focus Conference 2022

    GLOBENEWSWIRE

    Albireo Presents New Bylvay (odevixibat) Data at Annual ESPGHAN Congress

    GLOBENEWSWIRE

    Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

    GLOBENEWSWIRE

    Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN

    GLOBENEWSWIRE

    Albireo to Participate at Upcoming Investor Conferences

    GLOBENEWSWIRE

    Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022

    GLOBENEWSWIRE

    Albireo Reports Q1 2022 Financial Results and Business Update

    GLOBENEWSWIRE

    Albireo to Report Q1 2022 Financial Results on May 16

    GLOBENEWSWIRE

    Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM

    GLOBENEWSWIRE

    Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update

    GLOBENEWSWIRE

    NICE recommends Albireo’s Bylvay (odevixibat) for all PFIC types

    PHARMAFILE

    Albireo to Publish PICTURE Study Highlighting the Caregiver Impact of PFIC

    GLOBENEWSWIRE

    Albireo Announces Positive Topline Data from Phase 1 Study of A3907

    GLOBENEWSWIRE

    Albireo CMO Horn exits 5 months after US, EU approvals

    FIERCEBIOTECH

    Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer

    GLOBENEWSWIRE

    Albireo to Present at Upcoming Investor Conferences

    GLOBENEWSWIRE

    Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines Bylvay™

    GLOBENEWSWIRE

    Albireo Announces Bylvay® (odevixibat) Now Available in Germany

    GLOBENEWSWIRE

    Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)

    BIOSPACE

    Albireo Sells Priority Review Voucher (PRV) for $105 Million

    GLOBENEWSWIRE

    Albireo and Genpharm Announce Agreement to Commercialize Bylvay™

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.